Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians deciding on the treatment with better probability of success on an individual basis.
Flagship recruits ex-Magenta CEO to lead Ampersand; Biogen’s head of research leaves for Alltrna
Last Monday, Jason Gardner became the latest biotech veteran to join the sprawling biotech incubator Flagship Pioneering as a CEO-partner and as chief executive of